Novavax fell 8.2% after earnings, despite raising its full-year revenue framework and improving expense guidance. The transcript points to limited near-term visibility beyond partner milestones: Sanofi’s U.S. phase III trial is targeted for 2027, while the company describes broader partnership and pipeline opportunities as still developing.
Shares rose 14.0% as the market rewarded Novavax’s clear progress in expanding high-value partnerships, particularly with big pharma like Pfizer and Sanofi, signaling confidence in its capital-efficient, licensing-driven growth strategy rather than direct product sales.
Novavax demonstrated significant progress in Q3 2025, strengthening its partnership strategies and advancing its diversified R&D pipeline while achieving substantial cash flow, underscoring a shift towards long-term profitability and growth.